Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | MAOB | P27338 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661536 | 0.90 | NPC1 (0.83) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL20329669 | 0.89 | MAOA (0.56) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL20317336 | 0.89 | MAOA (0.59) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL20349982 | 0.84 | NPC1 (0.54) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL20346677 | 0.84 | MAOA (0.55) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL7331388 | 0.83 | KDM4E (0.86) | MAOANPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL29958722 | 0.82 | MAOA (1.00) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL789950 | 0.82 | MAOA (1.00) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL9078491 | 0.82 | NPC1 (0.71) | MAOANPC1RAB9AMAOBALDH1A1 | |
| SCHEMBL8867576 | 0.81 | MAOA (0.69) | MAOANPC1RAB9AMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3535243-B1 | SUBSTITUTED 9H-XANTHEN-9-ONE, 9H-THIOXANTHEN-9-ONE AND ACRIDIN-9(10H)-ONE DERIVATIVES AND RELATED COMPOUNDS CSF-1R INHIBITORS FOR THE TREATMENT OF CANCER | AUCKLAND UNISERVICES LTD (NZ) | 2021-12-15 | — | — | EP | disclosed |
| EP-3535243-B1 | SUBSTITUTED 9H-XANTHEN-9-ONE, 9H-THIOXANTHEN-9-ONE AND ACRIDIN-9(10H)-ONE DERIVATIVES AND RELATED COMPOUNDS CSF-1R INHIBITORS FOR THE TREATMENT OF CANCER | AUCKLAND UNISERVICES LTD (NZ) | 2021-12-15 | — | — | EP | disclosed |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-06-08 | — | — | US | disclosed |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | AUCKLAND UNISERVICES LIMITED (NZ) | 2021-06-08 | — | — | US | disclosed |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-09-12 | — | — | US | disclosed |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2019-09-12 | — | — | US | disclosed |
| EP-3535243-A2 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | Auckland Uniservices Limited (NZ) | 2019-09-11 | — | — | EP | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-8350041-B2 | Tricyclic δ-opioid modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-01-08 | — | — | US | disclosed |
| US-7982042-B2 | delta-opioid receptor agonists as analgesics having reduced side effects and antagonists as immunosuppressants, antiinflammatory agents, neurological, psychiatric , urological and reproductive conditions;N-{2-[10-(8-Allyl-8-aza-bicyclo[3.2.1]oct-3-yl)-10H-phenothiazine-3-yl]-phenyl}-acetamide | Janseen Pharmacautica NV (BE) | 2011-07-19 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | CARSON JOHN R | 2009-12-03 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589103-B2 | Especially 2-aminocarbonyl-9-(thio)xanthenylidene-8-aza-bicyclo[3.2.1] octane derivatives are used in pharmaceutical and veterinary compositions for treating mild to severe pain and various diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-1644373-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005003131-A1 | TRICYCLIC DELTA OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-13 | — | — | WO | disclosed |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298867-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | MAOA 948/4885NPC1 1561/4885RAB9A 2741/4885 |
| US-11028064-B2 | Tricyclic heterocyclic derivatives and uses thereof | CSF3R, CSF1R, FLT3 | MAOA 1536/4885NPC1 3799/4885RAB9A 2621/4885 |
| US-20050009860-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | MAOA 948/4885NPC1 1561/4885RAB9A 2741/4885 |
| US-20190276423-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF | CSF3R, CSF1R, FLT3 | MAOA 1536/4885NPC1 3799/4885RAB9A 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.